Servira

Generic name:phenobarbital, hyoscyamine sulfate, atropine sulfate and scopolamine hydrobromide
Dosage form: tablet, extended release
Drug class:Anticholinergics / antispasmodics

Medically reviewed by Drugs.com. Last updated on Dec 22, 2021.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Servira Description

Each Servira Extended Release tablet contains:
Phenobarbital, USP ..... 48.6 mg
(Warning: May be habit forming)
Hyoscyamine Sulfate, USP..... 0.3111 mg
Atropine Sulfate, USP..... 0.0582 mg
Scopolamine Hydrobromide, USP ..... 0.0195 mg

Servira Extended Release Tablets are designed to release the ingredients gradually to provide effects for up to twelve (12) hours.

In addition, each tablet contains the following inactive ingredients: DC Yellow #10 Aluminum Lake, FDC Blue #1 Aluminum Lake, FDC Yellow #6 Aluminum Lake, Hydroxypropyl Methylcellulose, Lactose, Magnesium Stearate, PEG 3350, Polyvinyl Alcohol, Povidone, Silicon Dioxide, Stearic Acid, Talc, Titanium Dioxide.

Servira - Clinical Pharmacology

This drug combination provides natural belladonna alkaloids in a specific, fixed ratio combined with phenobarbital to provide peripheral anticholinergic/antispasmodic action and mild sedation.

Indications and Usage for Servira

Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the following indications as "possibly" effective:

For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.

May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIO